title: Conversion of calcineurin inhibitors with mammalian target of rapamycin inhibitors after kidney transplant.
abstract: One way to overcome chronic allograft nephropathy induced by calcineurin inhibitors in immunosuppression protocols for organ transplants is to replace such inhibitors with mammalian target of rapamycin inhibitors, which are not clinically nephrotoxic because they have better renal function. If patients tolerate replacement, there could be a clear preference for mammalian target of rapamycin inhibitors as a maintenance immunosuppressant after renal transplant. This replacement could be sufficient if it were used for a certain time after calcineurin inhibitors. This review considers the conversion effects of calcineurin inhibitors with mammalian target of rapamycin inhibitors from the view point of kidney function during different periods after a kidney transplant.
authors: Tehran University of Medical Sciences, Tehran, IR Iran. hnikuinejad@yahoo.com
authors: Hassan
authors: H
authors: Nikoueinejad
authors: Alireza
authors: A
authors: Soleimani
authors: Abbas
authors: A
authors: Mirshafiey
authors: Aliakbar
authors: A
authors: Amirzargar
authors: Abdolfattah
authors: A
authors: Sarrafnejad
authors: Ideh
authors: I
authors: Kamkar
authors: Behzad
authors: B
authors: Einollahi
mesh_terms: D065095:Calcineurin Inhibitors; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007668:Kidney / Q000503:physiopathology; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D011379:Prognosis; D020123:Sirolimus / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus